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A REVIEW OF MULTIPLE 
SCLEROSIS TREATMENTS: 
INTERFERON BETA, 
GLATIRAMER ACETATE, 
FINGOLIMOD, AND 
NATALIZUMAB 
 
Abstract 
Multiple Sclerosis (MS) is an autoimmune disease in which the body’s own immune 
system works to demyelinate the myelin sheaths in the central nervous system. The 
beginning of the review will concentrate on the history of MS while also describing how 
MS, the disease, differs from that of normal immune responses. The review then shifts to 
the four different stages of MS and how to differentiate between the stages, since the 
treatment options are often dependent on the stage of MS that the patient is in. The 
main focus of this review is to take an in depth look on four specific medications for 
treating MS: Interferon Beta, Glatiramer Acetate, Fingolimod, and Natalizumab. Each 
medication will be described along with detailing their mechanism of action, or proposed 
mechanism of action, and the specific stages of MS that it has been proven to help. While 
there is no cure for MS, these medications have been implemented to help reduce the 
flare-up (relapses) of the symptoms produced by this autoimmune disease. The 
conclusions of the review offer some insight into newer research and possible paths that 
researchers should consider.  
   
Written by Ryan Golden 
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INTRODUCTION: 
Multiple Sclerosis (MS) is an autoimmune 
disease that effects the immune system. It 
can often be characterized as a process that 
causes demyelination of the central nervous 
system (1). The continual degradation of 
the myelin, which is important in the 
signaling pathways in the nervous system, 
can lead to disability. The interactions with 
the specific T-cells and the blood-brain 
barrier are of importance as well. While 
there continues to be advances in 
treatment to decrease the frequency of 
episodes of MS, there is still no cure for the 
disease (2). The pathological changes are 
initiated by extensive microglial activation 
which can lead to inflammatory lesions of 
the central nervous system (2).  
Because of the complexity of MS, 
and the fact that it effects each patient 
differently, the focus of research and 
treatments is to stop progression of 
disease, restore lost function, and 
ultimately to end MS for every patient (3). 
HISTORY OF MULTIPLE SCLEROSIS  
In 1946, there was little to be known on 
multiple sclerosis, but this was the year in 
which the National Multiple Sclerosis society 
was founded. The following year, the 
National MS society sponsored their first 
three research projects. However, it wasn’t 
until 1993 that the first treatment directly 
for MS was approved and 2010 the first oral 
treatment is brought to market (3). Funding 
continues for extended trials that continue 
to provide promise for continued 
exploration into treatments specific to MS. 
DISEASE PATHOLOGY 
How multiple sclerosis effects normal cells 
can be a starting point to help find possible 
treatments. Figure 1 shows the differences 
in immune functions between a normal cell 
and a MS cell.  
  
Figure 1 Normal vs. MS compromised cell: In panel 
A represents a normal suppression of myelin-
reactive T cells, while panel B represents how 
myelin-reactive T cells become activated in multiple 
sclerosis (4). 
Panel “A” depicts an immune cell’s 
normal reaction (4). The co-stimulatory 
molecules along with CTLA-4 are shown to 
regulate or suppress myelin-reactive T cells. 
“B” gives a representation of how the 
peripheral immune regulation is damaged 
(4). Some main differences to note are the 
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increase in co-stimulatory molecules and 
decrease in CTLA-4. These changes lead to 
the activation of myelin-reactive T cells that 
can cross the blood-brain barrier and 
initiate an inflammatory response (4).  
STAGES OF MULTIPLE 
SCLEROSIS: 
Multiple Sclerosis is a disease that can be 
characterized by an impaired nervous 
system. However, it can better be broken 
down into four main stages: 1) Clinically 
Isolated Syndrome 2) Relapse-Remitting 3) 
Primary Progressive and 4) Secondary 
Progressive (2).  
Clinical signs can often provide 
grounds to make a diagnosis of MS, 
magnetic resonance imaging (MRI), is an 
important method to support these findings 
(5). There is a set of criteria that must be 
met in order to provide the clinical 
diagnosis of multiple sclerosis. This is 
referred to as the “McDonald Criteria” by 
the International Panel on Diagnosis of MS 
(5). The McDonald Criteria was originally 
written in 2001, but with the latest 
revisions coming in 2013 (5). The McDonald 
Criteria contains the guidelines as to the 
different stages of MS and how to classify 
the patient’s stage based on the presenting 
conditions. It is important for the panel to 
continually look at revisions as the 
technology and research in MS advances.  
 
CLINICALLY ISOLATED SYNDROME 
Clinically isolated syndrome often refers to 
the first step in multiple sclerosis. This stage 
is a change in 2013 from the previous 
stages listed in McDonald’s Criteria (6). It is 
known to be an acute onset of 
demyelination located in the central 
nervous system (7). This syndrome is found 
in approximately 90 percent of initial 
presentations of MS and has become a key 
diagnosis tool for early detection of MS (7). 
There continues to be more 
research on the importance of early 
diagnosis and how it correlates to the 
clinical course of MS. As a result, a recent 
study by Kavaliunas, A.  et. al in 2017, 
worked to see the correlation of early 
treatment initiation and time line of 
disability.  
The study included 639 patients that 
were diagnosed with MS from 2001 to 
2007. The study followed up with patients 
in 99 months as the median amount of time 
(8). The aim of the study was to find the 
relationship of time of treatment to an 
irreversible score of 4 on the Expanded 
Disability Status Scale (EDSS).  
EDSS is a score 0-10 that is given as a 
determinant of the progression or stage 
that is the MS is inhibiting on the patient’s 
body. On this scale, a 0 would indicate that 
the neurological exam is normal whereas a 
10 would indicate death due to MS (9). 
Signs of disability begin to show up at a 
EDSS score of 2. The before mentioned 
study from 2017 found that patients who 
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started their treatment later had a greater 
risk of reaching EDSS 4, which was found to 
increase by 7.4 percent for every year in 
which they delayed the initiation of 
treatment (8). It was concluded that early 
treatment initiation had a positive 
correlation (p < 0.001) with a better clinical 
outcome (8). 
The before mentioned study is just 
one reason as to the importance of having 
the diagnostic ability to discover MS in the 
early stages. This can then give specialists 
the opportunity to monitor someone who 
may be at risk for developing multiple 
sclerosis.  
RELAPSE-REMITTING MULTIPLE 
SCLEROSIS  
Relapse-Remitting Multiple Sclerosis is 
defined as an occurrence, recurrence, or 
possible worsening of neurological 
dysfunction that lasts more than 24 hours 
(10). Of these dysfunctions, they must 
become stabilized or resolved either 
partially or completely after that time (10). 
Relapse-Remitting Multiple Sclerosis 
(RRMS) can be defined as having clearly 
defined disease relapses that follow with 
either a full recovery or with partial 
recovery (11). It is between these relapses 
that there is a period that lacks progression 
of the disease, i.e. remitting (11).  
This stage carries some defining 
elements to RRMS. The episode of relapse is 
dependent on the worsening of 
neurological function but must also have 
stability between attacks. A dissociation has 
not been found within the disease between 
patients that fully recover and those that 
only partially recover (11). 
PRIMARY-PROGRESSIVE MULTIPLE 
SCLEROSIS 
Primary-Progressive Multiple Sclerosis 
(PPMS) is defined as the disease 
progression from the onset of initial MS 
with occasional plateaus and also having 
temporary improvements that are minor 
(11). The essential point to this stage of MS 
is that it is characterized by an almost 
continuous, but gradual worsening baseline 
conditions of MS with minor improvements 
to conditions, but no distinct relapses (11). 
While RRMS does not have a 
continual increase in disability, PPMS has 
the increase in disability as time increases. 
The plateaus of minor improvement may or 
may not be seen in the patient, however it 
is more likely than not that plateaus will be 
seen (11).  
SECONDARY-PROGRESSIVE MULTIPLE 
SCLEROSIS  
Secondary-Progressive Multiple Sclerosis 
(SPMS) can be defined as RRMS as the 
initial course of disease, but is followed by 
progression that may or may not have 
relapses, minor remissions, or plateaus (11). 
It can be thought about that SPMS is the 
longitudinal outcome of some, but not all 
RRMS. 
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The distinguishing characteristic from RRMS 
and SPMS is the worsening of baseline 
conditions from one stage to the other (11).  
All four of the above stages can be 
diagnosed by clinical symptoms, but a MRI 
can give more accurate baseline 
information. The purpose of the MRI is to 
find evidence of brain and spinal lesion. 
Lesions can be seen due to the contrast that 
is injected. MRI was first used as a 
diagnostic tool in 1981 (3). 
TREATMENTS OF MULTIPLE 
SCLEROSIS 
In, 1993 the list of licensed multiple 
sclerosis treatments was zero, but as of 
March, 2017, 15 approved treatments exist. 
As stated earlier, there are no known cures 
for MS, but rather treatments that can 
provide temporary improvements or 
decrease in symptoms.  
The aim for most treatments is to 
help with symptoms to improve the quality 
of everyday life. The following is a subset of 
the growing list of disease-modifying 
treatments for multiple sclerosis. 
INTERFERON BETA 
WHAT IS INTERFERON BETA? 
Interferon beta is polypeptide that is 
produced by fibroblasts in the body. This 
polypeptide has anti-inflammatory effects 
because of its inhibition of T-lymphocyte 
proliferation (12). Only recombinant forms 
of interferon beta are given for MS 
treatment, interferon beta-1a and 
interferon beta-1b. Interferon beta-1a is 
given in doses of either 30 micrograms 
intramuscularly once a week or 
subcutaneously with doses of either 22 or 
44 micrograms, while interferon beta-1b is 
administered at a dose of 250 micrograms 
subcutaneously every other day (12). 
MECHANISM OF ACTION OF INTERFERON 
BETA 
Interferon beta has several proposed 
potential mechanisms of action in regard to 
multiple sclerosis. The precise mechanism 
by which interferon beta produces its anti-
inflammatory and immunomodulatory 
effects is still unclear (13). Those proposed 
methods include inhibition of T-cell 
activation and proliferation and also the  
blood-brain barrier effects (13). 
In an earlier section, the importance 
of the decreased activation of myelin-
reactive T-cells was discussed (4). It has 
been proposed that interferon beta 
achieves that. This drug promotes an 
increased expression of CTLA4, an 
important regulator for T-cells (13). It was 
also suggested in another study that 
interferon beta leads to an increase in Fas 
and CTLA4 induces apoptosis of such 
autoreactive T cells (14). It can then be 
suggested that the effects of interferon 
beta lower the chances that pathogenic T-
cells will become activated which leads the 
processes of the events that is initiated in 
MS cells.  
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Another proposed mechanism is interferon 
beta the decreases expression of molecules 
needed for antigen presentation. Figure 2 
shows that proposed mechanism. 
 
Figure 2. Interferon-Beta Cascade. The above figure 
displays interferon beta activation leads to 
decreased generation of antigen-specific T cells (15). 
A final proposed model of interferon 
beta mechanisms of action are the effects 
on the blood-brain barrier. Interferon beta 
increases the serum concentrations of 
soluble vascular cell adhesion molecule – 1 
(sVCAM) (13). Figure 3 shows the proposed 
model of interferon beta blood-brain 
barrier effects. 
 
Figure 3. Reaction to Interferon Beta Levels. The 
above figure illustrates how an increase or a possible 
decrease in interferon beta can halt T-cell adhesion 
with the vascular endothelial basement membrane 
and extravasation by central nervous system (14).  
STAGES THAT INTERFERON BETA BENEFITS 
Both types of interferon beta have been 
found to work in multiple stages of multiple 
sclerosis. For instance, in a study done in 
2006, it was proposed that interferon beta-
1b given at 250 micrograms subcutaneously 
every other day could be used as a 
treatment option to delay patient’s 
progression to RRMS from clinically isolated 
syndrome (16).  
The majority of the treatment was 
for RRMS in reducing the annualized relapse 
rate. Interferon beta was found to have 
approximately 30%-34% reduction of 
disability progression as well as decreased 
disease activity seen on MRI (12). 
Interferon beta has not been found 
to be effective for PPMS, because they are 
not designed for the pathogenic 
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mechanisms that are employed in PPMS 
(17). Whereas patients with SPMS have 
found some benefit, but for patients to 
experience this effect they must be 
experiencing superimposed relapses (12). 
GLATIRAMER ACETATE  
WHAT IS GLATIRAMER ACETATE? 
Glatiramer acetate is a group of synthetic 
peptides that resembles sequences of 
myelin basic protein, that often have 
lengths from 40-100 residues (12). It is 
thought to have its anti-inflammatory 
effects based on its role with Th2 and anti-
inflammatory cytokines (12). Glatiramer 
acetate can be given subcutaneously in 20 
mg daily or by 40 mg three times weekly 
(18).  
According to a study completed in 2015, 
the higher, but less frequent dose of 
glatiramer acetate had the following 
effects: 
• Reduction of annualized relapse rate 
in comparison to a placebo group 
• Suggest similar efficacy to that of 
the lower, more frequent dosage of 
glatiramer acetate 
• 50 percent reduction of incidence of 
side effects at injection site 
• Possibility to show an increase in 
convenience with MS patients (18) 
Due to this, recently there has been a 
switch in dosing from the daily 20 mg to the 
40 mg three times weekly. 
HOW DOES GLATIRAMER ACETATE WORK? 
The exact mechanism of glatiramer acetate 
is, again, not completely known. There are 
several proposed mechanisms that do exist 
today. 
The first is thought to deal with the 
activation of glatiramer acetate Th2 specific 
cells and the competition that occurs with 
MHC molecules on the antigen-presenting 
cells leads to suppression of the activation 
of myelin-reactive Th1 cells (19). Figure 4 
below, shows such proposed mechanism. 
 
Figure 4. Glatiramer Acetate Proposed Cascade.  
The above figure demonstrates how the 
presentation of glatiramer acetate as an antigen and 
leads to generation of glatiramer acetate specific 
Th2 cells is accomplished by either the high affinity 
of glatiramer acetate for the MHC or by an uptake of 
glatiramer acetate by an antigen presenting cell (15). 
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Another often suggested mechanism of 
action involves the blood-brain barrier. 
Figure 5 below shows this relationship. The 
actions can be best seen by contrasting the 
mechanism of interferon beta. (Gd means 
gadolinium, the element) 
 
Figure 5. Effects on BBB. The above figure shows the 
effects that interferon beta and glatiramer acetate 
have on the blood-brain barrier and eventually the 
brain (15). 
As seen in Figure 5, glatiramer acetate Th2 
cells cross the blood-brain barrier to affect 
the central nervous system function by a 
possible bystander suppression of the 
active myelin-reactive T cells. It also leads 
to no decrease in T cell migration and a 
delayed decrease of Gd-enhancing MRI 
activity (15). Gd enhancing MRI activity 
contains a correlation to infiltration of 
lymphocytes and also an increase in MMP 
levels is observed to lead to the disruptions 
of the blood-brain barrier (15) 
Other proposed mechanisms that 
are less understood include, glatiramer 
acetate lowering the production of 
cytokines by Th1 and imposing a 
neuroprotective effect by neurotrophic 
factors in the central nervous system (19). 
 STAGES OF MULTIPLE SCLEROSIS THAT 
GLATIRAMER ACETATE BENEFITS 
Glatiramer acetate at a subcutaneous 
dosage of 20 mg daily has been found to be 
effective, p=0.0005, for patients with 
clinically isolated syndrome when 
compared to a placebo trial of a 3 year time 
period involving 481 patients (20). 
Glatiramer acetate has been most 
effective in RRMS with the 20 mg daily dose 
having a mean reduction of annualized 
relapse rate of 29% (12). The glatiramer 
acetate that is given at 40 mg three times 
weekly was found to have a mean 
annualized relapse rate of 34%  (p<0.0001) 
(18). 
While glatiramer acetate has a high 
reduction of annualized relapse rate for 
clinically isolated syndrome and RRMS, it 
has not been investigated in SPMS and has 
shown no benefits for patients with PPMS 
(21). 
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FINGOLIMOD  
WHAT IS FINGOLIMOD? 
Fingolimod is the first oral form of a 
disease-modifying therapy that is approved 
for MS (22). It can be classified as a 
sphingosine 1-phosphate (S1P) receptor 
modulator (12). S1P is a natural lipid, in the 
lysophospholipids family; these lipids act as 
regulators for the pathogenesis of MS (22).  
 
Figure 6. Cells With S1P receptor. The above figure 
depicts a summary of the different cells that have 
the S1P receptor and are therefore affected by 
fingolimod (22). 
Past studies suggest that the S1P 
receptors that are found in figure 6 have 
been impaired in multiple sclerosis (22).   
Fingolimod is usually given in oral 
capsules at a dose of 0.5 mg or 1.25 mg 
daily (12). 
 
 
MECHANISM OF ACTION OF ORAL 
FINGOLIMOD 
Fingolimod is effective because it can cross 
the blood-brain barrier and directly affect 
the central nervous system (23). It has the 
capabilities to induce adherent junction 
assembly that can reduce the vascular 
leakage that is experienced in the 
pathogenesis of MS (22). 
Fingolimod works to inhibit the 
movement of the autoreactive lymphocytes 
from the lymph nodes and penetrate the 
central nervous system (12). Figure 7 
represents these such actions. 
 
Figure 7. Mechanism of Action of Fingolimod. The 
above figure represents how fingolimod works to 
down-regulate S1P receptors located on the 
lymphocytes in order to prevent the lymphocyte 
movement from the lymphoid tissues to lead to 
reduced penetration of destructive cells into the 
central nervous system (23).  
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Figure 8. Effects of Fingolimod. The figure above 
displays the effects that fingolimod treatment can 
employ on different cells within the central nervous 
system (22).  
STAGES OF MULTIPLE SCLEROSIS ORAL 
FINGOLIMOD HAS PROVIDED BENEFITS 
Fingolimod has proven to have therapeutic 
efficacy in patients with relapsing or 
relapsing-remitting MS (23). For RRMS that 
0.5 mg of fingolimod daily had a reduction 
of annualized relapse rate by 48-55 percent 
while also slowing disability by 25-30 
percent in a study of 1272 patients 
(p<0.001) (24).  
There continues to be ongoing 
investigations into the effectiveness of 
fingolimod for PPMS and SPMS, but 
additional trials are needed (22). 
 
 
 
NATALIZUMAB 
WHAT IS NATALIZUMAB?  
Natalizumab is a second line therapy that 
has been found to have an astoundingly 
high ARR at 68% (P<0.001) (12). 
Natalizumab is a defined as a monoclonal 
antibody that specifically blocks the 
interaction of the ligands at the a4-integrin 
which is a glycoprotein (25). 
Another interesting difference in 
natalizumab was the dosing instructions. In 
contrast to the earlier discussed 
treatments, natalizumab is a 300 mg, 
intravenous infusion that is given every four 
weeks (12).  
In addition to the reduced 
annualized relapse rate, a two-year, phase 
III trial considered to be pivotal to 
understanding natalizumab, also 
demonstrated that it lowered the rate of 
disability by 54% while also reducing 
gadolinium-enhancing lesions seen on MRI 
by 92% (p<0.001).  The study consisted of 
942 patients with 315 of those receiving 
placebo infusions as a control (26). 
However, with the high reductions 
mentioned earlier, there is an increased risk 
of developing a disease called progressive 
multifocal leukoencephalopathy (PML) with 
increased treatment time of natalizumab 
(27). In other words, the longer the period a 
patient receives natalizumab, there is an 
increase in the risk of the patient 
developing PML. PML is an infection from 
John Cunningham virus (JCV) attacking the 
oligodendrocytes of the CNS (12).  
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Due to the severity of PML, it has 
been imperative for MS patients to be 
screened in order to identify those patients 
who have been exposed to JCV because it is 
possible that viral reactivation can occur on 
immunosuppressed patients such as those 
with MS. STRATIFY JC virusä, which is an 
assay that measures anti-JC virus antibodies 
that are present in the blood to identify 
exposure to the JCV. Early results from the 
study showed that anti-JC virus antibodies 
were present in 54% of MS patients that 
were treated with natalizumab (27). 
Therefore, only patients that are JCV-
negative use natalizumab for more than 
two years and are tested every six months 
to see if their JCV status changes (12). 
HOW DOES NATALIZUMAB WORK? 
As stated before, natalizumab is 
monoclonal antibody that functions to 
block the a4-integrin, more specifically the 
a4b1-integrin (VLA-4) from binding. It’s 
believed mechanism of action is inhibition 
of autoreactive T cells entering into the 
CNS. In the same study, it was also thought 
that natalizumab could also be affected by 
pathogenic B cells in a similar way (28). This 
proves to be promising due to the fact that 
natalizumab binding to VLA-4 had a 49% 
reduction for B cells versus only 24.5% 
reduction of T cells. This was also 
accompanied by an increase in circulating B 
cells over T cells (29).  
The main concern of understanding how 
natalizumab works in RRMS is the 
interactions between the VLA-4, which is 
seen in mononuclear inflammatory cells, 
and vascular cell adhesion molecule-1 
(VCAM-1) expressed by cerebral vascular 
endothelial cells are known to express. This 
interaction leads to a reduction of leukocyte 
integration in the CNS which in turn lowers 
the activity of MS (30). This interaction is 
depicted in figure 9 below. 
 
Figure 9. Natalizumab effects on MS. The a4b1-
integrin binds to the VCAM-1, which then allows the 
autoreactive T cell to enter the CNS. Natalizumab 
does not allow the a4b1-integrin and VCAM-1 to 
bind and allow the T cell to penetrate the blood-
brain barrier to damage the myelin sheath (31).  
Another possible mechanism in which 
natalizumab helps with MS is Osteopontin 
levels in plasma, which are elevated in 
comparison to a healthy patient and even 
more so in CSF (30). In a 2 year study of 49 
patients with RRMS, it was shown that 
natalizumab reduced Osteopontin levels by 
31% (P<0.005). Also, it showed 
improvement in patients’ cognitive 
impairment (P<0.005) (32). It can be 
suggested from this data that increased 
Osteopontin levels can lead to cognitive 
impairment. 
As this treatment continues to become 
increasingly implemented, it continues to 
have possible mechanisms of action that 
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attempt to explain how it works. The main 
point being the interaction that occurs 
between the VLA-4 and VCAM-1.  
STAGES OF MULTIPLE SCLEROSIS THAT 
BENEFIT FROM NATALIZUMAB 
Natalizumab has the majority of its 
documented literature on how the 
treatment helps with RRMS, the 68% 
reduction in ARR stated earlier. As of March 
2017, natalizumab is only documented to 
be effective against RRMS. 
In 2011, there was a phase IIIb study on 
natalizumab in SPMS called ASCEND (30). 
However, in June of 2017 this trial was 
terminated for not having statistically 
significant findings. While this can be 
discouraging to researchers, there is still 
hope for finding a clinical benefit to 
understanding how the BBB is disturbed in 
progressive forms of MS. 
CONCLUSIONS 
Treatment for multiple sclerosis has come a 
long way in the last 24 years since the first 
drug treatments began to be produced. 
There looks to be continual upside to 
treatments of multiple sclerosis as ongoing 
trials are completed. Fingolimod continues 
to be an increasingly popular drug for the 
MS community because of the convenience 
of the oral version and the possibility of 
helping with non-relapsing forms of MS. 
While the focus of this review was on four 
specific treatments for the neurological 
disease pathway, it should also be noted 
that there are multiple different 
medications that MS patients use in order 
to treat other symptoms that are 
accompanied by this disease.  
For example, onabotulinum toxin type A 
(Botox), which is normally for the treatment 
of muscle stiffness, in 2011 was approved 
to treat urinary incontinence in MS 
patients. Botox is also used to help to 
control with spasticity (increase in tonic 
stretch reflexes) with injection directly into 
the skeletal muscle (33). 
FUTURE RESEARCH  
As stated above, future research needs to 
be done in order to continue to help people 
that are affected by this widely seen 
autoimmune disease. The increases in 
technology should continue to be a benefit 
to researchers in hopes to continue to 
enhance current medication, but also the 
possibility of development of new targeted 
treatments for MS (27). 
The most important research could come 
from an increase in studies to help clarify 
mechanism of action of these four drugs 
discussed in this review. Many of the 
mechanisms continue to remain unknown, 
which could impede research efforts. 
Knowing the possible mechanism could 
provide the opportunity to allow physicians 
to better select appropriate drugs for 
treatment (13, 30, 34). 
Another possibility in future research could 
focus on the ability of the drug to influence 
not only the immune system but also 
pathological changes that occur in MS. The 
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more that can be learned about the actual 
pathology, the better and more precise the 
treatments can be.  
Long term effects of the disease modifying 
treatments should also continue to be 
studied. Not only for the patient, but the 
physician so that they can estimate when a 
medication change should be made. 
A newer approach that is just starting to be 
explored is the effects that melatonin has 
on the immune response in MS. A study 
done in 2017 was the first to demonstrate 
that melatonin can reduce Th1 and Th22 
pathogenic responses in MS patients. The 
results also suggested that melatonin 
increases the ratio of anti-inflammatory vs. 
pro-inflammatory peripheral cells (35). This 
could provide yet another possible avenue 
for advancement in research.  
Throughout this review, the current forms 
of treatments have shown efficacy for 
RRMS, future research should also look into 
options for treatment for PPMS and SPMS. 
The main area of continued research should 
focus on the mechanisms of action of 
current treatments.   
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APPENDIX A 
Citations for “A Review of Multiple Sclerosis 
Treatments: Interferon Beta, Glatiramer 
Acetate, Fingolimod, and Natalizumab” 
were cited in NLM format.  
APPENDIX B 
The external reviewer for this review was 
Dr. Jerome Freeman a Neurologist at 
Sanford Neurology Clinic in Sioux Falls, SD. 
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He has been a tremendous help in his 
review of the first draft of this review. 
The following is his remarks on the first 
draft of this review: 
“I reviewed your manuscript “Review of 
Multiple Sclerosis and Treatment 
Options”.  You have a lot of good 
information in the paper.  I want to point 
out a couple of things.  It is not known for 
sure how interferon beta and glatiramer 
acetate work.  You provide some good 
explanations.  Generally it is thought that 
interferon tends to work more peripherally 
and glatiramer more in the central nervous 
system itself.  Both seem to reduce the 
annualized relapse rate (ARR) by about 
30%.  There are multiple other, newer 
therapies available now.  You mention 
Fingolimod.  It is estimated that Fingolimod 
causes an ARR reduction of about 54 to 
60%.  Another oral agent is 
Teriflunomide.  That causes an ARR 
reduction of about 31% and it’s not used as 
much as the other oral agents.  A third oral 
agent is Dimethyl Fumarate.  This causes an 
ARR reduction rate of about 53%.  Currently 
one of the most aggressive MS therapies 
available is Natalizumab.  This is a once a 
month IV injection.  It reduces the ARR by 
about 68%.  It is associated with a 
dangerous viral condition (progressive 
multifocal leukoencephalopathy 
(PML)).  This only tends to occur in people 
who carry the James Cunningham virus, 
which is about 50% of the 
population.  Generally this drug is used in 
people who are JC virus negative.  Other 
options include Alemtuzumab (monoclonal 
antibody).  A new drug that appears to be 
very effective is Ocrelizumab.  This also is a 
humanized monoclonal antibody.  Basically 
people get an infusion of this every 6 
months.  Thus you can see that there are 
considerably more options than the three 
therapies you mentioned.” 
After Dr. Freeman’s comments, I decided to 
narrow the title down to the four 
treatments reviewed as to be more specific. 
I chose to add Natalizumab because the 
PML component was interesting. 
Continuing with Dr. Freeman’s comments: 
“I’ll make some other brief comments 
about the manuscript.  In your introduction 
you note MS as a “failure of the central 
nervous system to perform 
remyelination”.  Actually I would 
characterize it foremost as a process that 
causes demyelination.  There is now 
evidence that in addition to attacking 
myelin, MS also has an adverse effect on 
axons.  On page three under your “stages of 
multiple sclerosis” the second paragraph 
starts with two phrases that aren’t 
complete sentences.  On page four, I think 
most experts refer to “relapsing-remitting 
multiple sclerosis” rather than using the 
term “relapse”.  The hallmark of this type of 
MS is that people get an attack and then 
recover (often 100%).  Sometimes some 
mild residual symptoms persist.  I think 
characterizing the “remission” is important 
rather than just the “lacks progression” that 
you mention.  On page five under 
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“secondary-progressive multiple sclerosis” 
you imply in the first paragraph that all 
people with RRMS proceed to a secondary 
progressive phase.  That is not necessarily 
the case.  I think it would be better to 
indicate that SPMS is the outcome of some 
patients with RRMS.  On page six (second 
paragraph) the first sentence is not 
complete.  Before reference #3 I think you 
would want to say something like “was 
mentioned”.  Also in the next sentence you 
say that interferon beta “does such that”.  I 
think it would be better to say “achieves 
that”.  On page seven at the bottom of the 
first column you indicate “affective”.  It 
should be “effective”.  Also in the second 
column on page seven the third bullet point 
mentions “50 percent reduction of 
incidence at reaction site”.  I’m not sure 
what that pertains to.” 
I took all of his grammatical and word 
choice suggestions to better the review. 
 
